118 related articles for article (PubMed ID: 10552092)
1. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu M; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
Eur J Nucl Med; 1998 May; 25(5):531-4. PubMed ID: 9575250
[TBL] [Abstract][Full Text] [Related]
3. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
4. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
[TBL] [Abstract][Full Text] [Related]
5. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
[TBL] [Abstract][Full Text] [Related]
6. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
[TBL] [Abstract][Full Text] [Related]
7. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
Ziebell M
Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
[TBL] [Abstract][Full Text] [Related]
9. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
[TBL] [Abstract][Full Text] [Related]
10. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S
J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589
[TBL] [Abstract][Full Text] [Related]
11. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls.
Tissingh G; Bergmans P; Booij J; Winogrodzka A; Stoof JC; Wolters EC; Van Royen EA
Eur J Nucl Med; 1997 Sep; 24(9):1171-4. PubMed ID: 9283113
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
[TBL] [Abstract][Full Text] [Related]
13. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
[TBL] [Abstract][Full Text] [Related]
15. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion.
Pinborg LH; Ziebell M; Frøkjaer VG; de Nijs R; Svarer C; Haugbøl S; Yndgaard S; Knudsen GM
J Nucl Med; 2005 Jul; 46(7):1119-27. PubMed ID: 16000280
[TBL] [Abstract][Full Text] [Related]
16. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers.
Lavalaye J; Booij J; Reneman L; Habraken JB; van Royen EA
Eur J Nucl Med; 2000 Jul; 27(7):867-9. PubMed ID: 10952500
[TBL] [Abstract][Full Text] [Related]
17. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain.
Madras BK; Gracz LM; Meltzer PC; Liang AY; Elmaleh DR; Kaufman MJ; Fischman AJ
Synapse; 1998 Jun; 29(2):105-15. PubMed ID: 9593101
[TBL] [Abstract][Full Text] [Related]
18. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
[TBL] [Abstract][Full Text] [Related]
19. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.
Pinborg LH; Videbaek C; Svarer C; Yndgaard S; Paulson OB; Knudsen GM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):623-31. PubMed ID: 11976800
[TBL] [Abstract][Full Text] [Related]
20. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
